Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs have been updated today, Feb. 1, 2021:
Effective March 1, 2021:
- IL-4 Inhibitor
- Oral Anticoagulant
- SA Oncology
- Soliris and Ultomiris
- Amifampridine
- Ampyra
- Arikayce
- ATTR Amyloidosis Onpattro
- ATTR Amyloidosis
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.